aspir
pneumonia
asp
develop
inhal
colon
oropharyng
materi
bacteriolog
studi
asp
earli
found
anaerob
organ
predominantli
isol
respiratori
specimen
basi
studi
antibiot
activ
anaerob
organ
becam
standard
care
patient
asp
howev
two
potenti
limit
studi
first
microbiolog
specimen
obtain
late
cours
ill
develop
necrot
pneumonia
empyema
isol
may
repres
superinfect
anaerob
organ
second
tracheal
sampl
contamin
oropharyng
flora
less
virul
anaerob
bacteria
rather
true
pulmonari
pathogen
recent
studi
use
protect
specimen
brush
avoid
oropharyng
flora
contamin
found
anaerob
organ
suggest
anaerob
antibiot
agent
might
dispens
absenc
sever
periodont
diseas
putrid
sputum
necrot
pneumonia
lung
abscess
format
moreov
role
anaerob
bacteria
aspir
syndrom
overemphas
clinic
practic
accord
current
infecti
diseas
societi
america
idsa
american
thorac
societi
at
guidelin
anaerob
coverag
communityacquir
pneumonia
cap
indic
patient
gingiv
risk
loss
conscious
seen
seizur
disord
alcohol
abus
patient
pneumonia
current
guidelin
recommend
narrow
criteria
justif
prescrib
anaerob
antibiot
found
signific
proport
patient
pneumonia
receiv
anaerob
antibiot
without
clear
indic
increas
intens
care
unit
icu
length
stay
associ
use
oesophag
motil
disord
specif
recommend
patient
healthcareassoci
pneumonia
hcap
absenc
risk
factor
risk
associ
inappropri
antibiot
use
well
known
includ
advers
drug
reaction
emerg
resist
pathogen
cost
howev
frequenc
anaerob
antibiot
use
pneumonia
absenc
evidencebas
indic
well
studi
studi
design
identifi
frequenc
inappropri
anaerob
antibiot
use
critic
ill
patient
pneumonia
lack
identifi
risk
factor
anaerob
infect
addit
sought
identifi
factor
influenc
decis
prescrib
anaerob
antibiot
inappropri
potenti
impact
prescrib
practic
singlecentr
prospect
cohort
studi
perform
among
adult
patient
age
admit
medic
intens
care
unit
icu
urbanbas
tertiari
care
teach
hospit
januari
may
primari
diagnosi
pneumonia
medic
icu
consist
five
separ
servic
primaryadmit
team
consist
intern
medicin
resid
pulmonarycrit
care
fellow
boardcertifi
pulmonari
attend
staff
clinic
diagnosi
pneumonia
made
primari
team
document
patient
chart
attend
staff
round
patient
admit
antibiot
prescrib
typic
next
day
opportun
chang
antibiot
regimen
felt
appropri
pneumonia
type
categor
primari
team
hcap
cap
asp
case
ventilatorassoci
pneumonia
vap
categor
hcap
antibiot
prescrib
primari
team
also
record
studi
period
choic
antibiot
usual
includ
vancomycin
cefepim
hcap
ceftriaxon
azithromycin
cap
addit
metronidazol
clindamycin
anaerob
coverag
desir
antibiot
broadli
cover
aerob
anaerob
microb
ie
piperacillin
tazobactam
ampicillinsulbactam
exclud
studi
would
difficulti
ascertain
whether
rational
antibiot
includ
treat
anaerob
organ
research
team
independ
assess
patient
determin
met
criteria
asp
coverag
detail
at
guidelin
influenc
clinic
decisionmak
process
primari
team
awar
diagnos
antibiot
choic
monitor
anaerob
antibiot
use
consid
appropri
follow
criteria
met
poor
periodont
condit
defin
gingiv
index
gi
score
perform
within
h
icu
admiss
fig
ii
loss
conscious
alcoholdrug
overdos
seizur
wit
aspir
document
histori
physic
iii
high
risk
chronic
aspir
oesophag
motil
disord
chronic
tracheostomi
iv
radiolog
evid
abscess
necrot
pneumonia
evalu
microbiolog
sputum
sampl
first
sputum
sampl
evalu
intub
patient
sampl
obtain
via
tracheal
aspir
bronchoalveolar
lavag
expector
sputum
obtain
patient
intub
analys
perform
stata
softwar
version
stata
corp
colleg
station
tx
usa
continu
variabl
compar
use
student
ttest
kruskalw
ranksum
test
case
nonnorm
distribut
variabl
express
respect
mean
ae
sd
median
interquartil
rang
iqr
categor
variabl
express
percentag
analys
use
chisquar
test
determin
independ
risk
factor
inappropri
anaerob
antibiot
use
univari
logist
regress
use
test
follow
factor
age
bmi
charlson
comorbid
index
risk
mortal
base
mortal
probabl
model
iii
zero
hour
score
clinic
diagnos
pneumonia
type
variabl
p
kept
model
continu
variabl
evalu
data
base
group
see
risk
linear
also
want
assess
whether
use
inappropri
antibiot
associ
either
prolong
icu
length
stay
lo
among
survivor
inhospit
mortal
multivari
linear
regress
use
evalu
icu
lo
logist
regress
use
evalu
mortal
risk
analys
follow
factor
assess
see
might
confound
relationship
age
bmi
charlson
comorbid
index
risk
mortal
base
score
clinic
diagnos
pneumonia
type
due
fact
normal
distribut
icu
lo
transform
use
squar
root
studi
approv
waiver
inform
consent
institut
review
board
henri
ford
hospit
detroit
michigan
irb
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
studi
period
patient
admit
icu
primari
diagnosi
pneumonia
screen
fig
twentytwo
patient
exclud
anaerob
antibiot
refractori
septic
shock
gastrointestin
infect
includ
clostridium
difficil
coliti
twentyeight
exclud
characterist
studi
popul
shown
tabl
differ
group
age
race
bmi
comorbid
predict
mortal
score
significantli
higher
aspir
group
expect
patient
clinic
diagnosi
asp
receiv
anaerob
antibiot
howev
signific
proport
patient
cap
hcap
also
receiv
anaerob
antibiot
respect
tabl
regardless
pneumonia
type
patient
meet
criteria
anaerob
antibiot
coverag
defin
methodolog
nonetheless
prescrib
anaerob
antibiot
tabl
half
patient
hcap
receiv
anaerob
antibiot
receiv
inappropri
moreov
patient
asp
receiv
anaerob
antibiot
onefourth
meet
criteria
appropri
anaerob
antibiot
use
overal
patient
receiv
inappropri
anaerob
antibiot
antibiot
discontinu
next
day
attend
staff
anaerob
antibiot
continu
remain
patient
p
signific
predictor
inappropri
anaerob
antibiot
use
includ
score
percentil
ci
p
patient
clinic
diagnosi
asp
ci
p
tabl
expect
score
signific
predictor
mortal
ci
p
control
sever
ill
inappropri
antibiot
use
ci
p
tabl
overal
median
icu
lo
day
iqr
signific
differ
icu
lo
three
type
pneumonia
diagnos
asp
day
iqr
hcap
day
iqr
cap
day
iqr
p
howev
patient
inappropri
receiv
anaerob
antibiot
signific
increas
icu
lo
compar
patient
receiv
antibiot
median
day
iqr
vs
day
iqr
respect
p
outcom
remain
signific
control
potenti
confound
overal
result
microbi
aetiolog
pneumonia
group
given
tabl
regardless
pneumonia
group
gramposit
bacteria
predomin
organ
signific
proport
also
gramneg
bacteria
anaerob
bacterium
isol
sputum
cultur
cap
patient
group
patient
grew
methicillinresist
staphylococcu
aureu
mrsa
pseudomona
aeruginosa
sputum
cultur
percent
group
influenza
antigen
detect
test
posit
admiss
idsa
at
guidelin
recommend
anaerob
coverag
cap
limit
patient
gingiv
risk
aspir
loss
conscious
seizur
alcohol
abus
oesophag
motil
disord
addit
role
antibiot
anaerob
coverag
hcap
vagu
less
clear
patient
guidelin
specif
recommend
use
unless
risk
factor
histori
suggest
aspir
event
studi
show
patient
admit
medic
icu
urban
teach
hospit
receiv
anaerob
antibiot
one
indic
inde
guidelin
follow
time
surprisingli
patient
diagnosi
asp
met
criteria
anaerob
antibiot
use
despit
patient
receiv
expect
low
percent
patient
cap
hcap
met
aspir
criteria
onethird
patient
nonetheless
receiv
anaerob
antibiot
number
factor
might
influenc
provid
decis
prescrib
anaerob
antibiot
absenc
clear
indic
data
suggest
sever
ill
independ
predictor
choic
prescrib
antibiot
even
clear
indic
twofold
increas
inappropri
anaerob
antibiot
use
predict
mortal
score
percentil
relationship
antibiot
prescript
sever
ill
report
other
children
respiratori
infect
like
prescrib
antibiot
clinician
perceiv
child
moder
sever
unwel
william
et
al
found
acut
physiolog
chronic
health
evalu
apach
score
signific
factor
affect
number
antibiot
prescrib
patient
one
possibl
explan
phenomenon
clinician
may
add
antibiot
perceiv
patient
ill
even
justif
use
surmis
effect
may
pronounc
cover
presum
anaerob
bacteria
microb
rare
isol
hospit
laboratori
surprisingli
diagnosi
asp
strongli
associ
use
anaerob
antibiot
despit
fact
patient
diagnosi
clear
criteria
receiv
thu
major
reason
use
anaerob
antibiot
inappropri
initi
diagnosi
asp
chart
review
reveal
clear
reason
diagnosi
patient
without
clear
indic
inde
oftentim
clear
rational
document
note
diagnosi
cap
hcap
asp
determin
survey
done
studi
may
reveal
possibl
reason
choos
diagnosi
pneumonia
type
one
potenti
reason
choic
antibiot
initi
diagnosi
pneumonia
type
initi
made
resid
fellow
rather
experienc
attend
staff
howev
partli
explain
choic
anaerob
antibiot
inappropri
anaerob
antibiot
chang
attend
staff
next
day
antibiot
penicillin
famili
cover
anaerob
could
also
use
cover
pneumonia
even
clinician
suspect
anaerob
reason
exclud
piperacillintazobactam
ampicillinsulbactam
institut
studi
period
paper
standard
antibiot
regimen
hcap
vap
combin
cefepim
vancomycin
cefepim
weak
anaerob
coverag
therefor
clindamycin
metronidazol
ad
vancomycin
cefepim
assum
clinician
tri
cover
anaerob
could
determin
clinician
intent
cover
anaerob
prescrib
piperacillintazobactam
ampicillinsulbactam
patient
receiv
antibiot
exclud
patient
without
clear
risk
factor
aspir
anaerob
organ
like
clinic
import
addit
data
show
percent
growth
similar
meet
criteria
asp
therefor
may
less
like
anaerob
organ
primari
microbiolog
aetiolog
pneumonia
furthermor
differ
distribut
microb
type
even
patient
met
criteria
asp
microbiolog
data
indic
cultur
organ
would
respons
standard
antibiot
without
need
resort
anaerob
coverag
use
inappropri
unjustifi
antibiot
without
consequ
indiscrimin
antibiot
use
associ
resist
advers
effect
develop
secondari
infect
includ
c
difficil
addit
studi
show
patient
inappropri
anaerob
antibiot
use
significantli
higher
icu
lo
associ
remain
even
control
predict
mortal
score
comorbid
measur
charlson
comorbid
index
number
import
limit
exist
studi
data
robust
enough
determin
whether
practic
pattern
effect
icu
lo
relat
clindamycin
metronidazol
addit
studi
limit
patient
pneumonia
icu
result
may
applic
set
gener
inpati
outpati
set
furthermor
singlecentr
studi
result
may
repres
local
practic
generaliz
criteria
use
measur
inappropri
anaerob
antibiot
use
wit
aspir
evid
periodont
diseas
comorbid
high
risk
aspir
part
base
gi
rate
gingiv
diseas
scale
consensu
regard
definit
poor
dentit
medic
literatur
gi
score
arbitrarili
select
indic
poor
periodont
condit
conceiv
cutoff
score
underestim
patient
receiv
anaerob
antibiot
nonetheless
outsid
risk
factor
asp
littl
evid
support
use
anaerob
antibiot
conclus
patient
pneumonia
high
rate
inappropri
use
anaerob
antibiot
associ
increas
icu
lo
although
sicker
patient
like
receiv
inappropri
antibiot
benefit
patient
without
clear
risk
factor
anaerob
infect
studi
evalu
impact
withhold
antibiot
patient
